128 related articles for article (PubMed ID: 9764140)
41. Perceived empowerment in people with a dual diagnosis of schizophrenia spectrum disorder and substance misuse.
Berry K; Allott R; Emsley R; Ennion S; Barrowclough C
Soc Psychiatry Psychiatr Epidemiol; 2014 Mar; 49(3):377-84. PubMed ID: 24141697
[TBL] [Abstract][Full Text] [Related]
42. National Institute for Health and Clinical Excellence (NICE) guideline: psychosis with coexisting substance misuse.
Abou Saleh M; Crome I
Addiction; 2012 Jan; 107(1):1-3. PubMed ID: 21939460
[No Abstract] [Full Text] [Related]
43. Clinical aspects of substance abuse in persons with schizophrenia.
Negrete JC
Can J Psychiatry; 2003 Feb; 48(1):14-21. PubMed ID: 12635559
[TBL] [Abstract][Full Text] [Related]
44. Feasibility of a skills training approach to reduce substance dependence among individuals with schizophrenia.
Shaner A; Eckman T; Roberts LJ; Fuller T
Psychiatr Serv; 2003 Sep; 54(9):1287-9. PubMed ID: 12954948
[TBL] [Abstract][Full Text] [Related]
45. Substance misuse in first-episode psychosis: 15-month prospective follow-up study.
Wade D; Harrigan S; Edwards J; Burgess PM; Whelan G; McGorry PD
Br J Psychiatry; 2006 Sep; 189():229-34. PubMed ID: 16946357
[TBL] [Abstract][Full Text] [Related]
46. Is schizophrenia a preventable disease?
Gureje O
West Afr J Med; 1993; 12(1):54-64. PubMed ID: 8512882
[TBL] [Abstract][Full Text] [Related]
47. Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects.
Sorbara F; Liraud F; Assens F; Abalan F; Verdoux H
Eur Psychiatry; 2003 May; 18(3):133-6. PubMed ID: 12763300
[TBL] [Abstract][Full Text] [Related]
48. Substance misuse in patients with schizophrenia: a primary care guide.
Lubman DI; Sundram S
Med J Aust; 2003 May; 178(S9):S71-5. PubMed ID: 12720527
[TBL] [Abstract][Full Text] [Related]
49. Schizophrenia, substance use, and brain morphology.
Scheller-Gilkey G; Lewine RR; Caudle J; Brown FW
Schizophr Res; 1999 Jan; 35(2):113-20. PubMed ID: 9988848
[TBL] [Abstract][Full Text] [Related]
50. Substance use disorders in schizophrenia: review, integration, and a proposed model.
Blanchard JJ; Brown SA; Horan WP; Sherwood AR
Clin Psychol Rev; 2000 Mar; 20(2):207-34. PubMed ID: 10721498
[TBL] [Abstract][Full Text] [Related]
51. An exploration of research into substance misuse and psychiatric disorder in the UK: what can we learn from history?
Crome IB
Crim Behav Ment Health; 2007; 17(4):204-14. PubMed ID: 17902120
[TBL] [Abstract][Full Text] [Related]
52. Substance abuse comorbidity in schizophrenia.
Schizophr Bull; 1990; 16(1):29-132. PubMed ID: 2333478
[No Abstract] [Full Text] [Related]
53. Group treatment for substance abuse in schizophrenia.
Addington J; el-Guebaly N
Can J Psychiatry; 1998 Oct; 43(8):843-5. PubMed ID: 9806092
[TBL] [Abstract][Full Text] [Related]
54. [Phenacetin addiction in female schizophrenic patients].
Laskowska D
Psychiatr Pol; 1969; 3(6):657-9. PubMed ID: 5367106
[No Abstract] [Full Text] [Related]
55. The link between schizophrenia and substance use disorder: A unifying hypothesis.
Khokhar JY; Dwiel LL; Henricks AM; Doucette WT; Green AI
Schizophr Res; 2018 Apr; 194():78-85. PubMed ID: 28416205
[TBL] [Abstract][Full Text] [Related]
56. Introduction to the special issue of Substance Use and Misuse on substance misuse and aggression.
Godlaski TM; Giancola P
Subst Use Misuse; 2009; 44(9-10):1183-7. PubMed ID: 19938913
[No Abstract] [Full Text] [Related]
57. Dimenhydrinate addiction in a schizophrenic woman.
Bartlik B; Galanter M; Angrist B
J Clin Psychiatry; 1989 Dec; 50(12):476. PubMed ID: 2600072
[No Abstract] [Full Text] [Related]
58. A patient-based voucher system of brief hospitalisation.
Little J; Stephens D
Aust N Z J Psychiatry; 1999 Jun; 33(3):429-32. PubMed ID: 10442801
[TBL] [Abstract][Full Text] [Related]
59. [Catamnestic study of patients with paranoid schizophrenia who have acted dangerously under delirious motivation].
Ianovskaia EV
Zh Nevropatol Psikhiatr Im S S Korsakova; 1966; 66(9):1392-7. PubMed ID: 6000211
[No Abstract] [Full Text] [Related]
60. Facing up to unpalatable evidence for the sake of our patients.
Mullen PE
PLoS Med; 2009 Aug; 6(8):e1000112. PubMed ID: 19688035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
